GZD 824

GZD 824 Basic information
Product Name:GZD 824
Synonyms:GZD-824; GZD 824;BENZAMIDE;4-Methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide;3-(2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;GZD8824;GZD824;GZD-824;GZD 824;GZD-824 Free;GZD 824;GZD824
CAS:1257628-77-5
MF:C29H27F3N6O
MW:532.56
EINECS:
Product Categories:Inhibitors
Mol File:1257628-77-5.mol
GZD 824 Structure
GZD 824 Chemical Properties
Boiling point 630.4±55.0 °C(Predicted)
density 1.39±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : ≥ 100 mg/mL (187.77 mM)
form A crystalline solid
pka9.04±0.40(Predicted)
Safety Information
MSDS Information
GZD 824 Usage And Synthesis
DescriptionGZD-824 is an orally available inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants including T315I (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively). It has been shown to suppress the proliferation of Bcr/Abl-positive K562 and Ku812 human chronic myelogenous leukemia cells (IC50s = 0.2 and 0.13 nM, respectively) and induce tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl.
UsesGZD824 is a orally bioavailable inhibitor that targets phosphorylated and non-phosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) kinases. It is a COVID19-related research product.
Tofacitinib Lenvatinib NS-398 Dacomitinib (PF299804) ACTIN FROM RABBIT MUSCLE Trametinib Palbociclib Cabozantinib Axitinib Nilotinib hydrochloride anhydrous

Email:[email protected] [email protected]
Copyright © 2025 Mywellwork.com All rights reserved.